Yao H, Zhang Q, Li H, Yin Y, et al. Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2026 Jul 1:S1470-2045(26)00193.
PMID: 42385760